ICICI Prudential Healthcare Fund-Growth
The fund is rated 4 stars. The strongest areas were investment selection within each asset type and investment selection within each industry, while balance between returns and downside risk provided some support. Higher annual fee of 2.07% and above-average fund size of Rs 6,802.61 crore were minor drawbacks.
This fund has a good track record with Asset Selection/Timing, a good track record with Stock Selection/Timing. It is important to note, however, that this fund has a 6802.61 AUM and a 2.07 expense ratio. Considering all these factors, we have rated this fund as 4.0 star.
எங்கள் score நீண்டகால performance, risk மற்றும் consistency-ஐ மதிப்பிடுகிறது — past returns மட்டும் அல்ல.
Returns
21 Sep 2026 நிலவரப்படி
Risk ratios
31 Aug 2026 நிலவரப்படி
Portfolio
31 Aug 2026 நிலவரப்படி
Market-cap பிரிவு
துறை ஒதுக்கீடு
Holdings (36)
| Holding | Fund-இன் % | மதிப்பு | பங்குகள் |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 12.31% | ₹861.02 Cr | 43,38,091 |
| Dr. Reddy's Laboratories Ltd. | 8.26% | ₹578.12 Cr | 50,08,009 |
| Cipla Ltd. | 5.76% | ₹402.74 Cr | 28,57,946 |
| Mankind Pharma Ltd. | 5.21% | ₹364.6 Cr | 15,07,093 |
| Alkem Laboratories Ltd. | 4.87% | ₹340.98 Cr | 6,39,791 |
| Divi's Laboratories Ltd. | 4.83% | ₹337.57 Cr | 3,56,579 |
| Others | 4.78% | ₹334.29 Cr | — |
| Biocon Ltd. | 4.68% | ₹327.26 Cr | 79,43,167 |
| Medplus Health Services Ltd. | 4.15% | ₹290.26 Cr | 43,17,751 |
| Cohance Lifesciences Ltd. | 4.08% | ₹285.73 Cr | 62,66,692 |
Fund விவரங்கள்
Long term wealth creation. An Equity Scheme that predominantly invests in Equity and Equity related securities of companies in Healthcare Sector.
The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies.
Exit load of 1% if redeemed within 15 days.